November 6, 2023 07:06 AM EST

AstraZeneca, Eledon and Alpine spell out kidney program successes: ASN roundup

Ayisha Sharma

News Reporter

Over the past few days, Big Pharma and biotech companies alike presented results at the American Society of Nephrology’s annual kidney week. Endpoints News sifted …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca, Eledon and Alpine spell out kidney program successes: ASN roundup

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Breaking down silos with a new quantitative approach to drug development

As­traZeneca, Ele­don and Alpine spell out kid­ney pro­gram suc­cess­es: ASN roundup

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

Lex­i­con's pres­i­dent to step down as de­ci­sion date looms; Sarep­ta wel­comes Lil­ly, GSK vet to board

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

Gilead­'s Kite un­cou­ples from Fo­s­un in Chi­na as Yescar­ta faces cov­er­age ob­sta­cles

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

AstraZeneca, Eledon and Alpine spell out kidney program successes: ASN roundup

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Breaking down silos with a new quantitative approach to drug development